Skip to content

Exercise Intervention in Patients With Metabolic Syndrome and Renal Disease: a Prospective Study

Exercise Intervention in Patients With Metabolic Syndrome and Renal Disease: a Prospective Study (EXRED)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06576518
Acronym
EXRED
Enrollment
50
Registered
2024-08-28
Start date
2021-06-10
Completion date
2024-05-27
Last updated
2024-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD, Metabolic Syndrome

Keywords

Adherence, Chronic Kidney Disease, Metabolic Syndrome, Obesity, Therapeutic Exercise

Brief summary

INTRODUCTION: Obesity (OB) and metabolic syndrome (MetS) are risk and progression factors for chronic kidney disease (CKD). However, the effect of OB/MetS intervention with exercise on renal function progression and proteinuria is unknown. OBJECTIVE: To analyse the effect of therapeutic exercise on MetS and main renal outcomes in patients with CKD. METHODOLOGY: This is a 6-month prospective exploratory study. Patients with stablished CKD (1-4) and MetS were treated with individualised incremental exercise (aerobic and resistance). Simultaneously, a plan of adherence was set up to promote compliance. Renal and metabolic outcomes were collected. The main renal parameters were: proteinuria, in isolated urine samples, and glomerular filtration rate (GFR), measured by iohexol DBS, at 0, 3 and 6 months. At the same time points, metabolic outcomes were measured: weight, dyslipidemia, insulin resistance and hypertension.

Interventions

OTHERTherapeutic exercise

An individualised incremental exercise programme was simultaneously supported by an adherence plan to assess and promote compliance.

Sponsors

Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias
CollaboratorOTHER
University of La Laguna
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age \>18 years * CKD of diverse aetiologies * estimated GFR ≥ 30 ml/min * BMI ≥ 27 kg/m2 associated to MetS or diabetes mellitus (DM) * stable renal function for at least 6 months before screening * ability to perform exercise

Exclusion criteria

* clinical conditions that exclude exercise therapy such as clinical instability, active infection, cancer, acute cardiovascular disease, advanced CKD, pulmonary hypertension, or limb amputations * inability to understand the protocol * severe psychiatric illness * allergy to iodine

Design outcomes

Primary

MeasureTime frameDescription
Changes in Glomerular filtration rate (GFR) and urine abulmin-creatinine ratio (UACR).Baseline, 3 and 6 monthsGFR and UACR were measured at baseline, 3 and 6 months, with the gold standard method of plasma clearance of iohexol (DBS technique) and urine analysis (isolated urine samples), respectively. The researchers expect a change in terms of GFR (improvement of hyperfiltration) and UACR reduction compared to baseline.

Secondary

MeasureTime frameDescription
Changes in body weight and MetS traits (Analytics).Baseline, month 3 and 6.Monthly, weight in kilograms, height in meters, waist circumference, hip circumference, will be measured. Also, BMI Body mass index (BMI): weight in kilograms divided by the square of the height in meters.Weight changes \>5% were expected at 6 months. Changes in Mets traits as a relative change from baseline (%) or as success in falling below the cut-off point of the MetS definition. To evaluate the improvements in metabolic risk factors profile: obesity, triglycerides, blood pressure and HDL cholesterol.hemogram (hematocrit, haemoglobin, white blood count), biochemist tests: creatinine, HbA1c, total, LDL and HDL cholesterol, triglycerides, uric acid, hepatic enzymes (ASAT, ALAT), levels of immunosuppression, albumin, creatinine, albuminuria, proteinuria in an isolated urinary samples.
Compliance-adherenceMonthlyTo ensure compliance, the following measures will be implemented: (a) contact by phone one time per week, (b) individual interview every month to reinforce lifestyle changes and follow all recommended in the exercise prescription; (c) the use of a gadget (xiaomi mi band) to see daily routines of patients and every training prescription, analysing the time, frequency, burned calories, velocity and distance, among others, to reach the established goal prescribed by the physiotherapist.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026